Abstract
The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Keywords: Influenza disease, natural compounds, therapeutic targets, drug development, drug repurposing, influenza hemagglutinin inhibitors, influenza NS1 inhibitors, influenza polymerase inhibitors.
Current Pharmaceutical Design
Title:Natural Products as Promising Therapeutics for Treatment of Influenza Disease
Volume: 21 Issue: 38
Author(s): Milan Sencanski, Draginja Radosevic, Vladimir Perovic, Branislava Gemovic, Maja Stanojevic, Nevena Veljkovic and Sanja Glisic
Affiliation:
Keywords: Influenza disease, natural compounds, therapeutic targets, drug development, drug repurposing, influenza hemagglutinin inhibitors, influenza NS1 inhibitors, influenza polymerase inhibitors.
Abstract: The influenza virus represents a permanent global health threat because it circulates not only within but also between numerous host populations, thereby frequently causing unexpected outbreaks in animals and humans with a generally unpredictable course of disease and epidemiology. Conventional influenza therapy is directed against the viral neuraminidase protein, which promotes virus release from infected cells, and the viral ion channel M2, which facilitates viral uncoating. However, these drugs, albeit effective, have a major drawback: their targets are of a highly variable sequence. As a consequence, the virus can readily acquire resistance by mutating the drug targets. Indeed, most seasonal A/H1N1 viruses and the 2009 H1N1 virus are resistant to M2 inhibitors, and a significant proportion of the seasonal A/H1N1 viruses are resistant to the neuraminidase inhibitor oseltamivir. Development of new effective drugs for treatment of disease during the regular influenza seasons and the possible influenza pandemic represents an important goal. The results presented here point out natural products as a promising source of low toxic and widely accessible drug candidates for treatment of the influenza disease. Natural products combined with new therapeutic targets and drug repurposing techniques, which accelerate development of new drugs, serve as an important platform for development of new influenza therapeutics.
Export Options
About this article
Cite this article as:
Sencanski Milan, Radosevic Draginja, Perovic Vladimir, Gemovic Branislava, Stanojevic Maja, Veljkovic Nevena and Glisic Sanja, Natural Products as Promising Therapeutics for Treatment of Influenza Disease, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002113426
DOI https://dx.doi.org/10.2174/1381612821666151002113426 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dermaseptins as Models for the Elucidation of Membrane-Acting Helical Amphipathic Antimicrobial Peptides
Current Pharmaceutical Biotechnology Grid-Based Technologies for In Silico Screening and Drug Design
Current Medicinal Chemistry The Role of Hypocarbia in the Development of Cystic Periventricular Leukomalacia
Current Pediatric Reviews 8-Azapurine Nucleus: A Versatile Scaffold for Different Targets
Mini-Reviews in Medicinal Chemistry Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant Agents
Current Neuropharmacology Mini-Review on SARS-CoV-2 Infection and Neurological Manifestations: A Perspective
CNS & Neurological Disorders - Drug Targets Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs
Current Pharmaceutical Design Discovery, SAR and Medicinal Chemistry of Herpesvirus Helicase Primase Inhibitors
Current Medicinal Chemistry - Anti-Infective Agents A Comparative Adsorption Study on Low-cost Synthetic, Nano and Doped ZnO for the Removal of Copper Surfactants Urea Complexes: Equilibrium, Kinetics, and Thermodynamics
Nanoscience & Nanotechnology-Asia Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Probing the Hypothesis of SAR Continuity Restoration by the Removal of Activity Cliffs Generators in QSAR
Current Pharmaceutical Design Patent Selections:
Recent Patents on Drug Delivery & Formulation Self Assembling Polymers as Polymersomes for Drug Delivery
Current Pharmaceutical Design Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry Interleukin-6 and Lung Inflammation: Evidence for a Causative Role in Inducing Respiratory System Resistance Increments
Inflammation & Allergy - Drug Targets (Discontinued) The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review
Current Medicinal Chemistry Bioavailability Through PepT1: The Role of Computer Modelling in Intelligent Drug Design
Current Computer-Aided Drug Design Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysautonomia
Current Drug Targets